Chugai To Plow $1bn+ Into New Core R&D Site
Executive Summary
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
You may also be interested in...
Chugai Turns To Digital Platform To Improve Biopharma Manufacturing
Chugai is starting to implement a new digital platform at manufacturing sites in Japan that it says will improve efficiency and flexibility.
Chugai Ups Forecast On Star Performer Hemlibra
Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.